Michael Chen
Chief Scientific Officer Seaport Therapeutics
Seminars
Thursday 17th September 2026
Transforming Anxiety & Mood Disorder Therapeutics: Advancing Lymphatic-targeting Prodrugs for Next-Generation Neuropsychiatric Medicine
1:00 pm
- Advancing clinically validated mechanisms with established efficacy and safety which have historically been limited by high first-pass metabolism, low bioavailability, and/or side effects, by applying the Glyph™ platform, a lymphatic-targeting prodrug technology, to overcome those limitations and invent innovative oral therapies
- Aiming to expand the clinical use of allopregnanolone, an endogenous neurosteroid with established antidepressant, anxiolytic, and sleep-promoting effects, through GlyphAllo (SPT-300), a novel, oral prodrug of allopregnanolone, designed to enhance oral bioavailability and enable once-daily oral dosing for patients with major depressive disorder
- Working toward enabling access to a clinically validated anxiolytic and antidepressant with GlyphAgo (SPT-320), a novel, oral prodrug of agomelatine, designed to enhance bioavailability and reduce pharmacokinetic variability compared to unmodified agomelatine at doses projected to reduce or eliminate the current need for routine liver function testing
Tuesday 15th September 2026
Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
3:15 pm
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required
Tuesday 15th September 2026
Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
3:15 pm
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required
